Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.
Stock data | 2023 | Change |
---|---|---|
Price | $0.2899544497232698 | N/A |
Market Cap | $5.66M | N/A |
Shares Outstanding | 19.52M | 0.00% |
Employees | 6.00 | N/A |
Shareholder Equity | 49.38M | -28.20% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.29 | N/A |
P/S Ratio | 5.63 | N/A |
P/B Ratio | 0.11 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0385 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.01M | N/A |
Earnings | -$1.90M | N/A |
EPS | -0.9954 | N/A |
Earnings Yield | -3.43 | N/A |
Gross Margin | 0.3846 | N/A |
Operating Margin | -1.68 | N/A |
Net income margin | -1.89 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $7.14M | N/A |
Cash on Hand | $835.38K | N/A |
Debt to Equity | 0.0467 | 80.76% |
Current Ratio | $2.31 | -61.56% |